LKT Laboratories, Inc.

Lorglumide Sodium

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID L5769
CAS No.
Chemical Name (±)-4-[(3,4-Dichlorobenzoyl)amino]-5-(dipentyl- amino)-5-oxopentanoic acid sodium salt
Synonym Lorglumide sodium salt



Formula $C_{22}H_{31}Cl_2N_2O_4Na$
Formula Wt. 481.39
Melting Point
Purity ≥98%
Solubility Soluble in methanol or water.

Bulk quanitites available upon request

Product ID	Size
L5769	25 mg
L5769	100 mg

Store Temp 4°C
Ship Temp Ambient
Description Lorglumide is an antagonist at cholestocystokinin (CCK) receptors; it exhibits antacid, anti-ulcerative, gastrointestinal motility modulating, and anticancer activities. Lorglumide decreases gastrointestinal motility and gastric secretion and is clinically used to treat ulcers, irritable bowel syndrome, constipation, and dyspepsia. Lorglumide also inhibits proliferation of colon cancer cells.

References

González-Puga C, García-Navarro A, Escames G, et al. Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin. J Pineal Res. 2005 Oct;39(3):243-50. PMID: 16150104.

Makovec F, Bani M, Cereda R, et al. Antispasmodic activity on the gallbladder of the mouse of CR 1409 (lorglumide) a potent antagonist of peripheral CCK. Pharmacol Res Commun. 1987 Jan;19(1):41-51. PMID: 3575382.

Makovec F, Bani M, Cereda R, et al. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung. 1987 Nov;37(11):1265-8. PMID: 3440035.